CYP39A1

Across TCGA pan-cancer cohorts, CYP39A1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CYP39A1 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CYP39A1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CYP39A1 expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

HNSC, LIHC, and ESCA are the cancer types where CYP39A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.170	0.662	.016	9	view →
LIHC	DFS	Median	All	0.081	0.527	.012	9	view →
ESCA	OS	Median	All	0.506	0.473	<.001	7	view →
SKCM	OS	Median	All	0.494	0.790	.006	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CYP39A1–HNSC (DFS)

Open the HNSC breakdown →